Cargando…

SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two arrangements: a soluble form (sDPP-4) and a plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Kifle, Zemene Demelash, Woldeyohanin, Alem Endeshaw, Demeke, Chilot Abiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511553/
https://www.ncbi.nlm.nih.gov/pubmed/34661092
http://dx.doi.org/10.1016/j.metop.2021.100134
_version_ 1784582790476464128
author Kifle, Zemene Demelash
Woldeyohanin, Alem Endeshaw
Demeke, Chilot Abiyu
author_facet Kifle, Zemene Demelash
Woldeyohanin, Alem Endeshaw
Demeke, Chilot Abiyu
author_sort Kifle, Zemene Demelash
collection PubMed
description COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two arrangements: a soluble form (sDPP-4) and a plasma membrane-bound form. Because other coronaviruses enter the cells by binding to DPP-4, it has been speculated that DPP-4 inhibitors may exert activity against COVID-19. Therefore, this review aimed to summarize the potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19. To include different studies, publications related to Dipeptidyl peptidase-4 inhibitor use and clinical outcomes from COVID-19 were searched from the databases such as Web of Science, PubMed, Medline, Elsevier, Google Scholar, and SCOPUS, via English key terms. A direct engrossment of DPP4 in COVID-19 needs to be elucidated, there is also evidence confirming that DPP4 inhibitors exert anti-fibrotic and modulate inflammation activity. Thus, the use of DPP-4 inhibitors could reduce mortality due to COVID-19 or improve the progression of COVID-19; this evidence may support the management of diabetic patients diagnosed with COVID-19; however more well-designed investigation is urgently required.
format Online
Article
Text
id pubmed-8511553
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85115532021-10-13 SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19 Kifle, Zemene Demelash Woldeyohanin, Alem Endeshaw Demeke, Chilot Abiyu Metabol Open COVID-19 in Metabolism COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two arrangements: a soluble form (sDPP-4) and a plasma membrane-bound form. Because other coronaviruses enter the cells by binding to DPP-4, it has been speculated that DPP-4 inhibitors may exert activity against COVID-19. Therefore, this review aimed to summarize the potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19. To include different studies, publications related to Dipeptidyl peptidase-4 inhibitor use and clinical outcomes from COVID-19 were searched from the databases such as Web of Science, PubMed, Medline, Elsevier, Google Scholar, and SCOPUS, via English key terms. A direct engrossment of DPP4 in COVID-19 needs to be elucidated, there is also evidence confirming that DPP4 inhibitors exert anti-fibrotic and modulate inflammation activity. Thus, the use of DPP-4 inhibitors could reduce mortality due to COVID-19 or improve the progression of COVID-19; this evidence may support the management of diabetic patients diagnosed with COVID-19; however more well-designed investigation is urgently required. Elsevier 2021-10-13 /pmc/articles/PMC8511553/ /pubmed/34661092 http://dx.doi.org/10.1016/j.metop.2021.100134 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle COVID-19 in Metabolism
Kifle, Zemene Demelash
Woldeyohanin, Alem Endeshaw
Demeke, Chilot Abiyu
SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
title SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
title_full SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
title_fullStr SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
title_full_unstemmed SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
title_short SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
title_sort sars-cov-2 and diabetes: a potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with covid-19
topic COVID-19 in Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511553/
https://www.ncbi.nlm.nih.gov/pubmed/34661092
http://dx.doi.org/10.1016/j.metop.2021.100134
work_keys_str_mv AT kiflezemenedemelash sarscov2anddiabetesapotentialtherapeuticeffectofdipeptidylpeptidase4inhibitorsindiabeticpatientsdiagnosedwithcovid19
AT woldeyohaninalemendeshaw sarscov2anddiabetesapotentialtherapeuticeffectofdipeptidylpeptidase4inhibitorsindiabeticpatientsdiagnosedwithcovid19
AT demekechilotabiyu sarscov2anddiabetesapotentialtherapeuticeffectofdipeptidylpeptidase4inhibitorsindiabeticpatientsdiagnosedwithcovid19